



DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health

National Institute on Drug Abuse; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Drug Abuse.

The meeting will be held as a virtual meeting and is open to the public, as indicated below. Individuals who plan to view the virtual meeting and need special assistance such as sign language interpretation or other reasonable accommodations to view the meeting, should notify Dr. Gillian Acca via email at gillian.acca@nih.gov ten days in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<http://videocast.nih.gov/>).

A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council on Drug Abuse

Date: February 3, 2026

Closed: 10:30 AM to 11:45 AM

Agenda: To review and evaluate grant applications

Open: 1:00 PM to 5:00 PM

Agenda: Presentations and other business of the Council

Meeting Format: Virtual Meeting

Place: National Institutes of Health
National Institute on Drug Abuse
Three White Flint North
11601 Landsdown Street
Bethesda, MD 20852

Contact Person: Susan R.B. Weiss, PHD
Director
Division of Extramural Research
Office of the Director
National Institute on Drug Abuse, NIH
Three White Flint North, RM 09D08
11601 Landsdown Street
Bethesda, MD 20852
301-443-6480
sweiss@nida.nih.gov

Contact Person: Gillian Acca, PHD
Health Scientist Administrator
Division of Extramural Research
Office of Extramural Policy
National Institute on Drug Abuse, NIH
Three White Flint North, RM 09C70
11601 Landsdown Street
Bethesda, MD 20852
301-827-5863
gillian.acca@nih.gov

The meeting identified below has been scheduled in the event the Council is unable to complete all agenda items identified for the February 3, 2026, meeting. Information on the agenda items and/or the necessity to hold the meeting listed below will be posted on the Institute/Center homepage (link identified below).

Name of Committee: National Advisory Council on Drug Abuse

Date: March 9, 2026

Closed: 10:30 AM to 11:45 AM

Agenda: To review and evaluate grant applications not completed at the February meeting

Open: 1:00 PM to 5:00 PM

Agenda: Presentations and other business of the Council not completed at the February meeting

Meeting Format: Virtual Meeting

Place: National Institutes of Health
National Institute on Drug Abuse
Three White Flint North
11601 Landsdown Street
Bethesda, MD 20852

Contact Person: Susan R.B. Weiss, PHD
Director
Division of Extramural Research
Office of the Director
National Institute on Drug Abuse, NIH
Three White Flint North, RM 09D08
11601 Landsdown Street
Bethesda, MD 20852
301-443-6480
sweiss@nida.nih.gov

Contact Person: Gillian Acca, PHD
Health Scientist Administrator
Division of Extramural Research
Office of Extramural Policy
National Institute on Drug Abuse, NIH
Three White Flint North, RM 09C70
11601 Landsdown Street

Bethesda, MD 20852
301-827-5863
gillian.acca@nih.gov

Any interested person may file written comments with the committee by forwarding the statement to Dr. Gillian Acca via email at gillian.acca@nih.gov. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page:
www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Zieta M. Charles,
Program Analyst,
Office of Federal Advisory Committee Policy.

[FR Doc. 2026-00820 Filed: 1/15/2026 8:45 am; Publication Date: 1/16/2026]